TY - JOUR
T1 - Current utilization of interferon alpha for the treatment of coronavirus disease 2019
T2 - A comprehensive review
AU - Lu, Ling Ying
AU - Feng, Po Hao
AU - Yu, Ming Sun
AU - Chen, Min Chi
AU - Lin, Alex Jia Hong
AU - Chen, Justin L.
AU - Yu, Lennex Hsueh Lin
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/2
Y1 - 2022/2
N2 - Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.
AB - Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.
KW - Coronavirus disease 2019
KW - COVID-19
KW - Interferon alpha
KW - SARS‑CoV‑2
KW - Severe acute respiratory syndrome coronavirus 2
UR - http://www.scopus.com/inward/record.url?scp=85123864356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123864356&partnerID=8YFLogxK
U2 - 10.1016/j.cytogfr.2022.01.001
DO - 10.1016/j.cytogfr.2022.01.001
M3 - Short survey
C2 - 35115233
AN - SCOPUS:85123864356
SN - 1359-6101
VL - 63
SP - 34
EP - 43
JO - Cytokine and Growth Factor Reviews
JF - Cytokine and Growth Factor Reviews
ER -
